HEPHAISTOS-Pharma raises €2 million (seed) to accelerate the development of their ONCO-Boost treatment

Altaïr Avocats has advised HEPHAISTOS-Pharma, a key player in the biotechnology sector, in its €2 million Seed fundraising. The deal will enable HEPHAISTOS-Pharma to advance the clinical development of their injectable immunostimulant ONCO-Boost.

Currently in development, ONCO-Boost is an innovative injectable immunostimulant designed to transform cold tumours, which are resistant to the immune system, into warm tumours, which are vulnerable to elimination. This breakthrough could radically transform the treatment of cancer, and positions HEPHAISTOS-Pharma as a future leader in immuno-oncology.

HEPHAISTOS-Pharma aims to establish, over time, strategic partnerships with Big Pharma in order to extend the applications of ONCO-Boost. The funds will enable HEPHAISTOS-Pharma to accelerate its clinical development, industrialise its manufacturing process and open a new subsidiary in Liège, Wallonia.

The fund-raising was orchestrated by Xista Science Ventures and the Fondation Fournier-Majoie, with the participation of Noshaq. It also benefited from the support of Angels Santé and historical investors.
 

The participants in this transaction:

Altaïr Avocats was involved in the:

Corporate with a team composed of: Philippe Beauregard, partner, and Jeanne Mucchielli, associate.

At the same time, the new investors were advised by Jones Day, represented by partner Jean-Gabriel Griboul and associate Gabriel Saint-Paul.